supaide / php-common Public Notifications Fork 0 Star 1 Code Issues Pull requests Actions Projects Security Insights Automate your workflow from idea to production GitHub Actions makes it easy to automate all your software workflows, now with world-class CI/CD. Build, test, and deploy...
supaide/php-commonmaster 1 Branch 6 Tags Code Folders and files Latest commit cyij up 9857ac2· Jan 6, 2018 History7 Commits src .gitignore composer.json About test Activity Custom properties Stars 1 star Watchers 1 watching Forks 0 forks Report repository Releases 6 tags ...
银诺医药正在研发的原创新药苏帕鲁肽(Supaglutide)已获得美国FDA批准开展非酒精性脂肪性肝炎(NASH)的临床试验,是我国首个获得美国FDA NASH临床批件的国产自主知识产权的人源化长效GLP-1受体激动剂。 NASH是一种严重的进行性非酒精性脂肪性肝病 (NAFLD),由肝脏脂肪堆积引起,并伴有炎症、肝细胞损伤,在某些情况下还伴有...
In the present study, we investigated supaglutide's therapeutic efficacy in rhesus monkeys with spontaneous metabolic dysfunction-associated steatohepatitis (MASH). Methods: 15 rhesus monkeys with biopsy-confirmed MASH were divided into three groups, receiving supaglutide 50 g/kg, supaglutide 150 g/...
7月25日,CDE官网显示,银诺医药苏帕鲁肽(Supaglutide)获批临床,用于治疗肥胖症。点击下载GLP-1系列专题:多肽药物研发演变苏帕鲁肽是一款人源化长效GLP-1受体激动剂,正在2型糖尿病,肥胖和NASH等代...
爱企查为您提供苏帕鲁肽supaglutide2023年企业商标信息查询,包括企业商标注册信息、商标logo,商标类别等企业商标信息查询,让您更轻松的了解苏帕鲁肽supaglutide商标信息,查询更多关于苏帕鲁肽supaglutide商标信息就到爱企查官网!
1、每根油条切三段,红薯去皮切1公分宽的长条 2、将红薯条穿入油条中 更多:https://www.bmcx.com/ 3、蛋打散,将穿好的油条沾上蛋液,低粉与淀粉混合后,再裹一层面粉 4、油锅烧四成热,将油条逐个放入炸脆至金黄,捞起沥油 5、全部再复炸一遍,沥干油 ...
Supaglutide, a novel GLP-1-IgG Fc fusion protein, exerts hypoglycemic effects in type 2 diabetic db/db mice and spontaneous diabetic monkeys. In this study, we investigated the pharmacokinetics and pharmacodynamics of supaglutide by single or repeated subcutaneous and intravenous injection (s) in...
Supaglutide (Supa) is a novel once-weekly, human-derived long-acting GLP-1 analogue developed for patients with type 2 diabetes. In this study, we investigated the safety, pharmacokinetics (PK) , pharmacodynamics (PD) and potential immunogenicity of single-dose subcutaneous injections of Supa in...
详细解释: 苏帕鲁肽是银诺医药首个管线产品,并已获得2型糖尿病适应症三期临床研究24周双盲期疗效终点。研究结果表明,苏帕鲁肽可以有效降低在饮食和运动干预后血糖控制不佳的2型糖尿病患者的血糖。“苏帕鲁肽是一个glp-1与免疫球蛋白的fc片段融合形成的融合蛋白,它克服了glp-1分子量小、半衰期短的特点,在体内形成一...